TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Comprehensive clinical development programs being initiated for each investigational candidate
The company has received five final approvals
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Innovent will supply sintilimab for the collaborated clinical trial
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Demonstrate significant bleed reduction in hemophilia A and B
Subscribe To Our Newsletter & Stay Updated
